He presented [**2133-4-21**] to [**Hospital3 22439**] after three days of epistaxis and one day of hematuria, petechiae on arms and legs, oral mucosal bleeding, and non-bloody emesis.
ROS: He reports a history of several months of abdominal, back, chest, hip and knee pain, and occasional sweats.
He denies visual disturbances, headache, chest pain, dyspnea, recent fevers, chills, night sweats, cough, hemoptysis, hematemesis, diarrhea, melena, hematochezia, or current joint pain or swelling.
Positive PPD status post 7.5 months of isoniazid self-discontinued [**1-/2133**]   Social History: Lives on [**Hospital1 64171**]with his aunt.
SKIN: Non-blanching petechial rash over upper arms and lower legs.
He underwent a biopsy of an enlarged retroperitoneal lymph node with pathology consistent with Hodgkin's lymphoma given presence of [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) **] cells.
Patient had five risk factors: albumin <4, hemoglobin <10.5, male gender, stage IV disease, and lymphocytopenia.
The patient was started on Neupogen and the patient's neutrophil count recovered [**2133-5-9**].
The patient's other counts improved prior to discharge, including platelets as below.
The patient developed a vesicular rash consistent with herpes zoster and was started on famvir as below.
PCP prophylaxis with bactrim was not started during admission as the patient's platelet count was not stable; the patient should discuss PCP prophylaxis with bactrim or pentamidine with his primary oncologist.
The patient did not have splenomegaly and lab work including DIC panel, HIT antibody (only weakly positive and not consistent with history), HIV antibody, and anti-platelet-antibodies were unrevealing.
The patient had significant bleeding and received a number of therapies, including chemotherapy as above, steroids, IVIG 2gm/kg, rituxan 325mg/m2, amicar intravenous and topical to oral mucosa, and danazol.
The patient was given a number of platelet transfusions for bleeding.
The patient finally had a response to these therapies and bleeding ceased.
The patient had a positive PPD one year prior and is status post 7.5 months of treatment with isoniazid per the Department of Health.
Infectious Disease was consulted and believed this was sufficient and no further treatment was necessary.
The patient was started on vancomycin.
Coverage was broadened to cefepime with further fevers.
Cefepime was discontinued when the patient was no longer neutropenic.
As the patient is without insurance, the patient was unable to receive intravenous antibiotic therapy.
After discussion with Infectious Disease, the patient's antibiotic coverage was changed from vancomycin to amoxicillin to complete a 14-day course.
This was likely secondary to nutritional deficiency and the patient responded to Vitamin K PO.
The patient was started on famvir and discharged with this medication as above.
The patient was started on amlodipine and blood pressure was subsequently well-controlled.
Medications on Admission: Tylenol PRN  Discharge Medications: 1.
Amlodipine 5 mg Tablet Sig: 1.5 Tablets PO DAILY (Daily).
Famciclovir 500 mg Tablet Sig: One (1) Tablet PO TID (3 times a day).
Amoxicillin 500 mg Capsule Sig: One (1) Capsule PO Q8H (every 8 hours) for 10 days.
Hodgkin's disease status post Cycle 1 BEACOPP 2.
Discharge Instructions: You were admitted for chemotherapy for Hodgkin's disease.
Please contact a physician if you experience fevers, chills, chest pain, shortness of breath, abdominal pain, nausea, vomiting, diarrhea, black stools or blood in your stools, pain with urinating or having to go more often, spontaneous bleeding or bruising, or any other concerning symptoms.
Please take your medications as prescribed.
- You should take amoxicillin 500 mg every eight hours for 10 days to treat a bacterical infection of the blood.
- You should take famvir 500 mg every eight hours ongoing to prevent shingles (herpes infection).
- You should take amlodipine 7.5 mg daily ongoing for high blood pressure.
- You should discuss starting bactrim or pentamidine for PCP pneumonia prophylaxis with your primary oncologist.
